/NVCT
NVCT Stock - Nuvectis Pharma, Inc.
Healthcare|BiotechnologyNASDAQ
$7.78-2.51%
$0.20 (-2.51%) • Dec 19
82
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.66
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+28.5%upside
Target: $10.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NVCT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.70 – $7.86
TARGET (TP)$10.00
STOP LOSS$7.16
RISK/REWARD1:3.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.28
52W High$11.52
52W Low$4.44
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-19,847,000 | $-22,897,000 | $-19,234,000 | $-12,894,000 | $-10,000 |
| Net Income | $-19,000,000 | $-22,260,000 | $-19,085,000 | $-12,890,000 | $-10,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.11 | $-1.43 | $-1.51 | $-1.09 | $-0.00 |
Company Overview
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$19
Average Target
↑ 144.2% Upside
Now
$17
Low
$19
Average
$21
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 2nd 2025 | Maxim Group | Initiation | Buy | $17 |
| March 17th 2025 | Laidlaw | Initiation | Buy | $19 |
| July 13th 2022 | Ladenburg Thalmann | Initiation | Buy | $21 |
Earnings History & Surprises
NVCTBeat Rate
38%
Last 16 quarters
Avg Surprise
-6.8%
EPS vs Estimate
Beats / Misses
6/9
1 met exactly
Latest EPS
$-0.44
Q4 2025
EPS Surprise History
Q1 24
-2.5%
$-0.41vs$-0.40
Q2 24
+37.5%
$-0.25vs$-0.40
Q3 24
0.0%
$-0.26vs$-0.26
Q4 24
+7.7%
$-0.24vs$-0.26
Q1 25
-28.6%
$-0.36vs$-0.28
Q2 25
+10.0%
$-0.27vs$-0.30
Q3 25
-20.0%
$-0.30vs$-0.25
Q4 25
-83.3%
$-0.44vs$-0.24
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 24, 2026 | $-0.26 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.24 | $-0.44 | -83.3% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-0.25 | $-0.30 | -20.0% | ✗ MISS |
Q2 2025 | May 6, 2025 | $-0.30 | $-0.27 | +10.0% | ✓ BEAT |
Q1 2025 | Feb 25, 2025 | $-0.28 | $-0.36 | -28.6% | ✗ MISS |
Q4 2024 | Nov 5, 2024 | $-0.26 | $-0.24 | +7.7% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.26 | $-0.26 | 0.0% | = MET |
Q2 2024 | May 7, 2024 | $-0.40 | $-0.25 | +37.5% | ✓ BEAT |
Q1 2024 | Mar 5, 2024 | $-0.40 | $-0.41 | -2.5% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.38 | $-0.37 | +2.6% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.34 | $-0.38 | -11.8% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-0.44 | $-0.27 | +38.6% | ✓ BEAT |
Q1 2023 | Mar 7, 2023 | $-0.38 | $-0.48 | -26.3% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.27 | $-0.42 | -55.6% | ✗ MISS |
Q3 2022 | Aug 5, 2022 | $-0.24 | $-0.28 | -16.7% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.23 | $-0.32 | -39.1% | ✗ MISS |
Q1 2022 | Feb 7, 2022 | $-0.85 | $-0.18 | +79.1% | ✓ BEAT |
Q1 2022 | Jan 14, 2022 | — | $-0.40 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.47 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.00 | — | — |
Latest News
Nuvectis Pharma Initiated Phase 1b Study Of NXP900 In Combination With Astrazeneca's Tagrisso (Osimertinib) In Patients With EGFRmut+ NSCLC
📈 PositiveBenzinga•Dec 17, 2025, 12:09 PM•Also:
Nuvectis Pharma,To Discuss Key NXP900 Preclinical And Clinical Data To Date And Strategy For Monotherapy And Combination Components Of NXP900 Phase 1b Clinical Program At Key Opinion Leader Meeting
📈 PositiveBenzinga•Nov 25, 2025, 01:04 PM
Nuvectis Pharma Q3 EPS $(0.44) Misses $(0.25) Estimate
📉 NegativeBenzinga•Nov 4, 2025, 01:30 PM
Nuvectis Pharma Provides Highlights For NXP900 Poster Presentations For 2025 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics In Boston
➖ NeutralBenzinga•Oct 27, 2025, 12:19 PM
Nuvectis To Present NXP900 Clinical Safety And FAT1 Tumor Data At AACR-NCI-EORTC 2025 International Conference
➖ NeutralBenzinga•Oct 16, 2025, 12:02 PM
Frequently Asked Questions about NVCT
What is NVCT's current stock price?
Nuvectis Pharma, Inc. (NVCT) is currently trading at $7.78 per share. The stock has moved -2.51% today.
What is the analyst price target for NVCT?
The average analyst price target for NVCT is $10.00, based on 1 analyst.
What sector is Nuvectis Pharma, Inc. in?
Nuvectis Pharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NVCT's market cap?
Nuvectis Pharma, Inc. has a market capitalization of $0.20 billion, making it a small-cap company.
Does NVCT pay dividends?
No, Nuvectis Pharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARMP
Armata Pharmaceuticals, Inc.
$6.16
Mkt Cap: $0.2B
CGEN
Compugen Ltd.
$1.52
Mkt Cap: $0.1B
CRDF
Cardiff Oncology, Inc.
$2.57
Mkt Cap: $0.2B
CYBN
Cybin Inc.
$7.18
Mkt Cap: $0.4B
IPHA
Innate Pharma S.A.
$1.75
Mkt Cap: $0.1B
MIST
Milestone Pharmaceuticals Inc.
$2.15
Mkt Cap: $0.2B
MOLN
Molecular Partners AG
$4.39
Mkt Cap: $0.2B
RANI
Rani Therapeutics Holdings, Inc.
$1.51
Mkt Cap: $0.1B
SAVA
Cassava Sciences, Inc.
$2.17
Mkt Cap: $0.1B
TNXP
Tonix Pharmaceuticals Holding Corp.
$17.09
Mkt Cap: $0.1B
Explore stocks similar to NVCT for comparison